Top > Search of International Patents > HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF

HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF

Foreign code F170009093
File No. (S2016-0059-N0)
Posted date May 30, 2017
Country WIPO
International application number 2016JP080815
International publication number WO 2017069113
Date of international filing Oct 18, 2016
Date of international publication Apr 27, 2017
Priority data
  • P2015-205999 (Oct 20, 2015) JP
Title HAIR-GROWTH PROMOTING COMPOSITION AND USAGE THEREOF
Abstract The present invention relates to providing a new hair-growth or hair-restoration promoting composition or a composition that prevents hair loss. More specifically, provided is a composition containing an iNOS inhibitor as an active ingredient. The present invention achieves an advantageous effect of hair growth or hair restoration by injecting the composition containing the iNOS inhibitor as the active ingredient into a mammal. The iNOS inhibitor used may be a low-molecular compound, an antibody, or into a nucleic acid medicine, such as an antisense oligo or siRNA. Also provided is a method for screening effective substances for promoting hair growth or hair restoration or for preventing hair loss.
Outline of related art and contending technology BACKGROUND ART
Is generally the stimulation of hair growth, growth phase (anagen), catagen, rest (telogen) (non-patent document 1) classified into. In the case of human hair, then the growth period after 2-7 years, catagen, telogen phase through, the hair loss.
As the main function of the hair, trauma to provide protection from direct sunlight, and the like to prevent loss of body temperature, hair, mediate important social and communication, decrease the amount of the hair may result in the decrease of the QOL of people.
The cause of alopecia, male pattern alopecia, seborrheic alopecia, senile alopecia, alopecia areata, alopecia results from the administration of an anticancer drug, scarring alopecia, alopecia or the like occurs after birth can be classified as a post-partum. However, these hair loss is a measure for, at the moment it is not well-established.
The current, major pharmaceutical accepted as hair growth, hair growth agents include, minoxidil and finasteride is. Minoxidil is, initially, the main working vasodilation orally as a therapeutic agent for hypertension is medication developed, hypertension therapeutic agent to a patient undergoing treatment was adapted, and dilates the blood vessels, such as hirsutism is promotes the regeneration of hair was observed, the external preparation of the hair again as medical developed pharmaceutical product. Minoxidil K ATP is sensitive to vasodilation via activation of the channel. Is the primary function of the minoxidil, the initial growth phase of hair follicles from the telogen phase shift to the prompt to promote hair growth, hair growth in hair follicles to grow thick hair, and is considered to be such as to. DHT (dihydrotestosterone) bonding to the receptor of the sebaceous gland, an effect to inhibit the growth of hair. Finasteride is, the male hormone testosterone DHT is an enzyme that converts 2 to inhibit 5 - α-reductase, acts by suppressing the generation of DHT. Male sex hormones of benign prostate hyperplasia caused by a therapeutic agent for the treatment of male pattern alopecia (AGA) have been developed to apply to a pharmaceutical product.
These agents are presently commercially available but, to measures against hair loss, more effective pharmaceutical is still demanded.
Nitric oxide synthase (NOS, EC1.14.13.39) is, nitric oxide and nitrogen oxide (NO) is an enzyme involved in the synthesis. Is always constant in the presence of an intracellular NOS of constitutive NOS (cNOS) and, due to stress-induced inflammation NOS (iNOS, NOS2) classified, is further cNOS, (NOS1) of the neuronal eNOS nNOS (NOS3) of the vascular endothelium are classified (non-patent document 2). Is iNOS, known as an inflammatory stimulus such as lipopolysaccharide (LPS) induced by the, immune system, cardiovascular system, such as expressed in the lung. Is iNOS, defense against a pathogen known to be involved. Heretofore, iNOS inhibitors, the use of anti-inflammatory drugs or as anti-cancer agents, such as for the purpose of treating sepsis have been developed, including cosmetic supplements or cosmetics, to the development of therapeutically effective agents not yet provided.
Scope of claims (In Japanese)[請求項1]
発毛もしくは育毛の促進または脱毛の予防に用いるための組成物であって、iNOS阻害剤を有効成分として含有することを特徴とする、組成物。
[請求項2]
iNOS阻害剤が1400W、アミノグアニジン、BYK191023、AMT塩酸塩、AR-C102222、L-NIO、L-NIL、S-エチルイソチオ尿素、S-メチルイソチオ尿素、S-アミノエチルイソチオ尿素、2-イミノピペリジン、ブチルアミン、ONO-1714、L-NG-ニトロアルギニン、L-NG-モノメチルアルギニン、L-ニトロアルギニンメチルエステル、およびデキサメタゾンから成る群から選択される化合物である、請求項1記載の組成物。
[請求項3]
iNOS阻害剤がモノクローナル抗体またはその断片である、請求項1記載の組成物。
[請求項4]
iNOS阻害剤がアンチセンスオリゴヌクレオチドである、請求項1記載の組成物。
[請求項5]
iNOS阻害剤がsiRNAである、請求項1記載の組成物。
[請求項6]
医薬組成物である、請求項1記載の組成物。
[請求項7]
美容用組成物である、請求項1記載の組成物。
[請求項8]
美容サプリメントである、請求項1記載の組成物。
[請求項9]
経口剤である、請求項1記載の組成物。
[請求項10]
注射剤である、請求項1記載の組成物。
[請求項11]
外皮用剤である、請求項1記載の組成物。
[請求項12]
哺乳動物における発毛もしくは育毛を促進または脱毛を予防するための方法であって、iNOS阻害剤を該哺乳動物に投与することを含む、方法。
[請求項13]
哺乳動物がヒトである、請求項12記載の方法。
[請求項14]
哺乳動物がイヌ、ネコ、またはヒツジである、請求項12記載の方法。
[請求項15]
哺乳動物における発毛もしくは育毛を促進または脱毛を予防するための方法であって、iNOSを阻害する工程を含む、方法。
[請求項16]
発毛もしくは育毛の促進または脱毛の予防に用いるための医薬の製造における、iNOS阻害剤の使用。
[請求項17]
発毛もしくは育毛の促進または脱毛の予防に有効な物質をスクリーニングするための方法であって、
i)in vitroでiNOSと試験物質とを接触させる工程、
ii)iNOSの活性を測定する工程、および
iii)該試験物質がiNOSの活性を低下させるか否かを決定する工程
を含む、方法。
[請求項18]
iNOSの活性を増強する組成物を投与してiNOSの活性を増強する工程を含む、毛髪の成長を阻害する方法。
[請求項19]
NOを発生させる組成物を対象に投与する工程を含む、毛髪の成長を阻害する方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • Inventor
  • SHINOZAKI, Shohei
  • SHIMOKADO, Kentaro
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close